Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 490

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 490
---
 of State of the State of Delaware an amendment to the Company’s amended and restated certificate of incorporation to change the date by which the Company must consummate a business combination to June 9, 2024. On March 7, 2024 at a special meeting of stockholders of the Company, stockholders holding 119,572 shares properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.58 per share, adjusted for applicable taxes in the amount of

F-51

TABLE OF CONTENTS

### IRIS ACQUISITION CORP

### NOTES TO FINANCIAL STATEMENTS
$60,000 taxes, including, but not limited to, franchise tax, excise tax and income tax. Following such redemptions, approximately $1,265,669 will be left in trust, subject to adjustment for applicable taxes, including, but not limited to, franchise tax, excise tax and income tax and 7,187,037 shares will remain outstanding.

Subsequent to December 31, 2023, the Company disbursed extension payments to the trust account totaling $45,684.

On March 9, 2024, the parties to the Business Combination Agreement, amended the Business Combination Agreement, PIPE Equity Subscription Agreement, and Convertible Note Subscription Agreement to extend the termination of these agreements to July 31, 2024.

On March 11, 2024, the Company entered into an administrative support agreement (the “Agreement”) with Arrow Capital Management LLC (“Arrow”). Pursuant to the Agreement, Arrow will provide certain office space, utilities and secretarial and administrative support (the “Services”) to the Company. In exchange for the Services, the Company will pay to Arrow $10,000 per month, beginning January 1, 2024, and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation.

On March 13, 2024, the December 2022 unsecured promissory note with the Sponsor was amended and restated to remove the amount equal to 150% of the principal amount upon the closing of a business combination.

<div align='center'>F-52</div>

TABLE OF CONTENTS

LIMINATUS PHARMA, LLC CONDENSED BALANCE SHEETS
(in thousands)

| ​                                       
 ​                                       
 ASSETS                                  
 Current assets:                         | ​ 
 ​ 
 ​